Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability-Reference-Cited by-同舟云学术

Indomethacin Pharmacodynamics Are Altered by Surfactant: A Possible Challenge to Current Indomethacin Dosing Guidelines Created Before Surfactant Availability

Published:2010-01-10 Issue:4 Volume:31 Page:505-510
ISSN:0172-0643
Container-title:Pediatric Cardiology
language:en
Short-container-title:Pediatr Cardiol

Author:

McPherson Christopher,Gal Peter,Ransom J. Laurence,Carlos Rita Q.,Dimaguila Mary Ann V. T.,Smith McCrae,Davonzo Christie,Wimmer John E.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Pediatrics, Perinatology and Child Health

Link

http://link.springer.com/content/pdf/10.1007/s00246-009-9628-6.pdf

Reference33 articles.

1. Alpert BS, Lewins MJ, Rowland DW, Grant MJA, Olley PM, Soldin SJ, Swyer PR, Coceani F, Rowe R (1979) Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus—clinical and echocardiographic assessments of response. J Pediatr 95:578–582

2. Bose CL, Laughon M (2006) Treatment to prevent patency of the ductus arteriosus: beneficial or harmful? J Pediatr 148:713–714

3. Brash AR, Hickey DE, Graham TP, Stahlman MT, Oates JA, Cotton RB (1981) Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med 305:67–72

4. Brown Y, Kandrotas RJ, Douglas JB, Gal P (1988) High performance liquid chromatographic determination of indomethacin serum concentration. J Chromatogr 459:275–279

5. Chorne N, Leonard C, Piecuch R, Clyman RI (2007) Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 119:1165–1174

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Blood Prostaglandin E2 Metabolite Levels among Infants Born Preterm with Patent Ductus Arteriosus: A Prospective Study;The Journal of Pediatrics;2024-09

2. CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus;Pharmacogenomics;2019-08

3. Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus;Pediatric Cardiology;2018-02-21

4. Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions;Current Pediatric Reviews;2016-05-06

5. The interplay between drugs and the kidney in premature neonates;Pediatric Nephrology;2013-11-12